Impact of vaccinations and infectious diseases on the risk of melanoma - Evaluation of an EORTC case-control study

European Journal of Cancer

Volumn 39, Issue 16, 2003, Pages 2372-2378

  Krone, B ^a   Kolmel K F ^a   Grange, J M ^b   Mastrangelo, G ^c   Henz, B M ^d   Botev, I N ^e   Niin, M ^f   Seebacher, C ^g   Lambert, D ^h   Shafir, R ⁱ   Kokoschka, E M ^j   Kleeberg, U R ^k   Gefeller, O ^l   Pfahlberg, A ^l  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^f Estonian Cancer Center   (Estonia)

^g ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^k Int Oncol and Laboratory Medicine   (Germany)

^l UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

more..

Author keywords

Anticancer defence; BCG; Infection; Innate immunity; Melanoma; Vaccination; Vaccinia

Indexed keywords

BCG VACCINE; INFLUENZA VACCINE; VACCINIA VACCINE;

ADULT; AGED; ARTICLE; BCG VACCINATION; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CHILDHOOD; CONTROLLED STUDY; CORRELATION ANALYSIS; EUROPE; FEMALE; FEVER; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; ISRAEL; MALE; MELANOMA; PRIORITY JOURNAL; SKIN CANCER; TUBERCULOSIS; VIRUS INFECTION;

EID: 0141817861     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00625-7     Document Type: Article

References (29)

1. Stanford J.L., Stanford C.A., Grange J.M. Environmental echoes. Sci. Prog. 84:2001;105-124.
2. Martinez F.D., Holt P.G. Role of microbial burden in aetiology of allergy and asthma. Lancet. 354(Suppl. 2):1999;12-15.
3. Bonnani P. Demographic impact of vaccination. a review Vaccine. 17:1999;120-125.
4. Kristensen I., Aaby P., Jensen H. Routine vaccinations and child survival. follow up study in Guinea-Bissau, West Africa Br. Med. J. 321:2000;1435-1439.
5. Abel U., Becker N., Angerer R.et al. Common infections in the history of cancer patients and controls. J. Cancer Res. Clin. Oncol. 117:1991;339-344.
6. Albonico H.U., Bräker H.U., Hüsler J. Febrile infectious childhood diseases in the history of cancer patients and matched controls. Med. Hypotheses. 51:1998;315-320.
7. Kölmel K.F., Gefeller O., Haferkamp B. Febrile infections and malignant melanoma. results of a case-control study Melanoma Res. 2:1992;207-211.
8. Kölmel K.F., Pfahlberg A., Mastrangelo G.et al. Infections and melanoma risk. results of a multicentre EORTC case-control study Melanoma Res. 9:1999;511-519.
9. Mastrangelo G., Rossi C.R., Pfahlberg A.et al. Is there a relationship between influenza vaccinations and the risk of melanoma? A population-based case-control study. Eur. J. Epidemiol. 16:2000;777-782.
10. Pfahlberg A., Kölmel K.F., Grange J.M.et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox. results of the FEBIM study J. Investig. Dermatol. 119:2002;570-575.
11. Fitzpatrick T.B. The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 124:1988;869-871.
12. Gallagher R.P., McLean D.I., Yang C.P.et al. Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic naevi in children. Similarities to melanoma: the Vancouver Mole study. Arch. Dermatol. 126:1990;770-776.
13. Von Mutius E., Martinez F.D., Fritzsch C., Nicolai T., Roell G., Thiemann H.H. Prevalence of asthma and atopy in two areas of East and West Germany. Am. J. Respir. Crit. Care. 149:1994;358-364.
14. Henig EM. 200 Jahre Pockenimpfstoff in Deutschland. In Krafft F. (Ed.) Quellen und Studien zur Geschichte der Pharmazie, vol. 73. Stuttgart, Germany, Wissenschaftliche Verlagsgesellschaft Stuttgart, 1997 pp 1-284.
15. Rosenthal S.R., Crispin R.G., Thorne M.G., Piekarski N., Raisys N., Retig P.G. BCG vaccination and leukaemia mortality. J. Am. Med. Assoc. 222:1972;1543-1544.
16. Grange J.M., Stanford J.L. BCG vaccination and cancer. Tubercle. 71:1990;61-64.
17. Comstock G.W., Livesay V.T., Webster R.G. Leukaemia and BCG, a controlled trial. Lancet. 2:1971;1062-1063.
18. Härö A.S. The effect of BCG-vaccination and tuberculosis on the risk of leukaemia. Develop. Biol. Standard. 58:1983;433-449.
19. Fine P.E.M. The BCG story. lessons from the past and implications for the future Rev. Infect. Dis. 11(Suppl. 2):1989;353-359.
20. Menzies D. What does tuberculin reactivity after bacille Calmette-Guérin tell us? Clin. Infect. Dis. 31(Suppl. 3):2000;71-74.
21. Comstock G.W., Martinez I., Livesay V.T. Efficacy of BCG vaccination in prevention of cancer. J. Natl. Cancer Inst. 54:1975;835-839.
22. Salonen T., Saxen L. Risk indicators in childhood malignancies. Int. J. Cancer. 15:1975;941-946.
23. Lundbäck H. Skillnader i nordisk vaccinationspolitik. Nordisk Med. 87:1972;228-230.
24. Balkwill F., Mantovani A. Inflammation and cancer. back to Virchow? Lancet. 357:2001;539-545.
25. Grufferman S., Wang H.H., DeLong E.R., Kimm S.Y., Delzell E.S., Faletta J.M. Environmental factors in the etiology of rhabdomyosarcoma in childhood. J. Natl. Cancer Inst. 68:1982;107-113.
26. Mizzen L. Immune responses to stress proteins. applications to infectious diseases and cancer Biotherapy. 10:1998;173-198.
27. Mayr A., Mayr B. A new concept in prophylaxis and therapy. paramunization by poxvirus inducers Presq. Vet. Bras. 19:1999;91-98.
28. Iida K., Fujita K., Hirai H.et al. Preventive effects of polysaccharides extracted from human tubercle bacilli (specific substance of Maruyama) on colonic carcinogenesis in rats. Cancer Detect. Prevt. 21:1997;476-482.
29. Stanford J.L., Stanford C.A., Baban B., Grange J.M. Therapeutic vaccination for cancer. the potential value of mycobacterial products Int. J. Pharm. Med. 12:1999;191-195.